ranolazine has been researched along with Cardiomyopathy, Hypertrophic in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argirò, A; Baldini, K; Cappelli, F; Coppini, R; Dei, LL; Favilli, S; Ferrantini, C; Gabriele, M; Marchi, A; Marchionni, N; Maurizi, N; Olivotto, I; Passantino, S; Tassetti, L; Tomberli, A; Zampieri, M; Zocchi, C | 1 |
| Elliott, PM | 1 |
| Belardinelli, L; Cerbai, E; Coppini, R; Ferrantini, C; Gentile, F; Matucci, R; Mazzoni, L; Mugelli, A; Olivotto, I; Palandri, C; Pioner, JM; Poggesi, C; Rossi, A; Tesi, C; Tosi, B | 1 |
| Fischer, KL; Heitner, SB | 1 |
| Antzelevitch, C; Barajas-Martínez, H; Goodrow, RJ; Hu, D; Joyce, F | 1 |
| Carrier, L; Christ, T; Cuello, F; Eschenhagen, T; Flenner, F; Friedrich, FW; Geertz, B; Maier, LS; Reischmann, S; Schwedhelm, E; Söhren, KD; Stathopoulou, K; Ungeheuer, N; Wagner, S; Weinberger, F | 1 |
| Gentry, JL; Hurdle, M; Mentz, RJ; Wang, A | 1 |
| Bargelli, V; Bartolucci, G; Belardinelli, L; Cerbai, E; Coppini, R; Crocini, C; Ferrantini, C; Gentile, F; Laurino, A; Mazzoni, L; Mugelli, A; Olivotto, I; Pioner, JM; Poggesi, C; Rotellini, M; Sacconi, L; Santini, L; Tardiff, J; Tesi, C | 1 |
| Cecchi, F; Coppini, R; Ferrantini, C; Girolami, F; Olivotto, I; Rossi, A; Tomberli, B | 1 |
| Belardinelli, L; Cerbai, E; Coppini, R; Del Lungo, M; Fan, P; Ferrantini, C; Mugelli, A; Olivotto, I; Poggesi, C; Sartiani, L; Stillitano, F; Suffredini, S; Tesi, C; Tosi, B; Yacoub, M; Yao, L | 1 |
1 review(s) available for ranolazine and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Diet, Healthy; Disopyramide; Exercise Therapy; Health Status; Healthy Lifestyle; Humans; Obesity; Ranolazine; Risk Reduction Behavior; Sleep Apnea Syndromes | 2019 |
9 other study(ies) available for ranolazine and Cardiomyopathy, Hypertrophic
| Article | Year |
|---|---|
Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center.
Topics: Acetanilides; Angina Pectoris; Canada; Cardiomyopathy, Hypertrophic; Humans; Prospective Studies; Ranolazine; Treatment Outcome | 2023 |
Evolving Story of Clinical Trials in Hypertrophic Cardiomyopathy.
Topics: Cardiomyopathy, Hypertrophic; Double-Blind Method; Humans; Ranolazine; Sodium Channel Blockers | 2018 |
Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Hypertrophic; Cohort Studies; Dose-Response Relationship, Drug; Exercise; Female; Humans; Male; Middle Aged; Myocardium; Pyridines; Ranolazine; Sodium; Sodium Channel Blockers; Triazoles | 2018 |
Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy.
Topics: Acetanilides; Action Potentials; Cardiomyopathy, Hypertrophic; Cells, Cultured; Heart Rate; Humans; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers | 2013 |
Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Animals; Calcium; Cardiomyopathy, Hypertrophic; Dose-Response Relationship, Drug; Isoproterenol; Mice; Myocytes, Cardiac; Phosphorylation; Ranolazine; Sodium Channel Blockers | 2016 |
Ranolazine for Treatment of Angina or Dyspnea in Hypertrophic Cardiomyopathy Patients (RHYME).
Topics: Aged; Angina Pectoris; Cardiomyopathy, Hypertrophic; Cardiovascular Agents; Dyspnea; Female; Humans; Male; Middle Aged; Pilot Projects; Ranolazine | 2016 |
Ranolazine Prevents Phenotype Development in a Mouse Model of Hypertrophic Cardiomyopathy.
Topics: Animals; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomyopathy, Hypertrophic; Disease Models, Animal; Echocardiography, Doppler; Excitation Contraction Coupling; Genetic Predisposition to Disease; Heart Rate; Hypertrophy, Left Ventricular; Magnetic Resonance Imaging; Male; Membrane Potentials; Mice, Inbred C57BL; Mice, Transgenic; Microscopy, Confocal; Mutation; Myocardial Contraction; Myocytes, Cardiac; Phenotype; Ranolazine; Sodium; Sodium Channel Blockers; Time Factors; Troponin T; Ventricular Dysfunction, Left; Ventricular Function, Left | 2017 |
[Management of refractory symptoms in hypertrophic cardiomyopathy with restrictive pathophysiology: novel perspectives for ranolazine].
Topics: Acetanilides; Adult; Cardiac Pacing, Artificial; Cardiac Surgical Procedures; Cardiomyopathy, Hypertrophic; Cardiomyopathy, Restrictive; Cardiovascular Agents; Catheter Ablation; Enzyme Inhibitors; Female; Humans; Pacemaker, Artificial; Piperazines; Ranolazine; Severity of Illness Index; Treatment Outcome | 2012 |
Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy.
Topics: Acetanilides; Action Potentials; Adult; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomyopathy, Hypertrophic; Case-Control Studies; Diastole; Female; Humans; Male; Middle Aged; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Potassium Channels; Ranolazine; Signal Transduction; Sodium Channel Blockers | 2013 |